RxDoctor Payments Data

Schuyler Cook, DO

Internal Medicine · Chillicothe, OHNPI 1952802779

Payments from drug & device makers

$3,966in general payments, 2019–2025

Across 231 payments — averaging $17.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$771
  • Lilly USA, LLC$464
  • AbbVie$409
  • Bayer$319
  • Otsuka America Pharmaceutical, Inc.$253
  • Phathom Pharmaceuticals, Inc.$246
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$3,966100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,966 in reported general payments places this provider in the 85th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$17,667
Medicare patients
74
Services billed
716

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide47$80,070
OzempicSemaglutide62$64,432
MounjaroTirzepatide43$54,076
JardianceEmpagliflozin28$35,748
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$27,321
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$11,023
SymbicortBudesonide/Formoterol Fumarate20$4,988
Soliqua 100-33Insulin Glargine/Lixisenatide12$3,598
Albuterol Sulfate HfaAlbuterol Sulfate75$2,781
Dabigatran EtexilateDabigatran Etexilate Mesylate11$2,098
SynthroidLevothyroxine Sodium21$2,045
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$1,414
PaxlovidNirmatrelvir/Ritonavir14$1,413
Levothyroxine Sodium110$1,253
Atorvastatin Calcium93$1,114

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$771$144,502109 claims
Lilly USA, LLCMounjaro$464$54,07643 claims
Boehringer IngelheimJardiance$59$35,74828 claims
GSKTrelegy Ellipta$119$27,32119 claims
AstraZenecaBreztri Aerosphere, Symbicort$118$16,01134 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$34$3,59812 claims
AbbVieSynthroid$409$2,04521 claims
PfizerPaxlovid$214$1,41314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Chillicothe

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →